Susan Theresa Iannaccone, MD | DuchenneXchange

welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!
Healthcare Providers

Susan Theresa Iannaccone, MD

Healthcare Provider
Children's Medical Center of Dallas
The University of Texas Southwestern Medical Center
1935 Medical District Drive
Dallas, Texas, United States

Dr. Susan Iannaccone is currently working as pediatric neurologist with clinical focus on neurorehabilitation at Children’s Medical Center of Dallas of the University of Texas Southwestern Medical Center. For the past two decades, she has worked on management protocols and outcome measures for these disorders: spinal muscular atrophy (SMA) and Duchenne muscular dystrophy (DMD).

She holds 4 pediatric neuromuscular clinics per week, all of which are official Muscular Dystrophy Association (MDA) sponsored clinics. Nearly 100% of all children diagnosed with DMD/SMA in north Texas are referred to her team either by their primary care provider, another child neurologist, or by parents who read about their program on the internet. Broad areas of her research interest include neuromuscular medicine, neurorehabilitation, Duchenne muscular dystrophy, and spinal muscular atrophy.

Dr. Iannaccone is also the professor of neurology and pediatrics at the University of Texas Southwestern Medical Center. Currently, she is site-PI for more than half a dozen clinical trials in spinal muscular atrophy (SMA) and DMD. She is also the Co-Investigator for the UT Southwestern NeuroNEXT grant from NINDS, and Associate Director for the NIH funded, UT Southwestern Wellstone Muscular Dystrophy Center. She is also the site PI for the Muscular Dystrophy Association (MDA) sponsored DMD Research Network.

 

Representative Publications:

Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Characterization of pulmonary function in 10-18 year old patients with Duchenne muscular dystrophy

The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study

Liquid formulation of pentoxifylline is a poorly tolerated treatment for duchenne dystrophy

The PedsQL in pediatric patients with Duchenne muscular dystrophy: feasibility, reliability, and validity of the Pediatric Quality of Life Inventory Neuromuscular Module and Generic Core Scales

rareRelated